Jeremy Bender - 15 Feb 2024 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Issuer symbol
DAWN
Transactions as of
15 Feb 2024
Transactions value $
-$116,114
Form type
4
Filing time
20 Feb 2024, 18:14:48 UTC
Previous filing
09 Feb 2024
Next filing
03 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise +3,562 +0.5% 712,991 15 Feb 2024 Direct F1
transaction DAWN Common Stock Options Exercise +4,750 +0.67% 717,741 15 Feb 2024 Direct F1
transaction DAWN Common Stock Options Exercise +11,687 +1.6% 729,428 15 Feb 2024 Direct F1
transaction DAWN Common Stock Sale -$116,114 -7,615 -1% $15.25 721,813 16 Feb 2024 Direct F2
holding DAWN Common Stock 221,837 15 Feb 2024 See footnote F3
holding DAWN Common Stock 300,025 15 Feb 2024 See footnote F4
holding DAWN Common Stock 251,636 15 Feb 2024 See footnote F5
holding DAWN Common Stock 270,226 15 Feb 2024 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -3,562 -12% $0 24,942 15 Feb 2024 Common Stock 3,562 Direct F1, F7
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -4,750 -8.3% $0 52,250 15 Feb 2024 Common Stock 4,750 Direct F1, F7
transaction DAWN Restricted Stock Unit (RSU) Options Exercise $0 -11,687 -6.2% $0 175,313 15 Feb 2024 Common Stock 11,687 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
F3 Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
F4 Represents shares held by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023.
F5 Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.
F6 Represents shares held by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023.
F7 The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.